在体外和在体内评估以沙丁衍生的螺旋氧indoles作为抗结核药物候选药物
Fernanda Rodrigues de Lima1, Jéssika de Oliveira Viana1,2, Aleff Cruz de Castro1
1Programa de Pós-Graduação em Química, Universidade Federal da Paraíba (UFPB), João Pessoa, Brazil.
Chemical biology & drug design
|July 1, 2025
概括
新的异酸衍生物A16和A17在体外对抗多药耐药结核病菌株表现出强烈的活性. 这些化合物无毒,具有有利的类似药物的特性,表明它们作为新型抗结核病剂的潜力.
科学领域:
- 药用化学 医学化学
- 微生物学 微生物学
- 药物发现 药物发现 药物发现
背景情况:
- 结核病 (TB) 是一个重大的全球卫生挑战,随着多种耐药性Mycobacterium结核病 (MTB) 菌株的增加,需要新的治疗药物.
- 伊萨衍生物是开发新的抗结核药物的一类有前途的化合物.
研究的目的:
- 为了合成和评估新的异酸衍生物用于体外抗结核病活性.
- 评估强效抗结核病候选药物的细胞毒性和药理动力学特性.
- 探索潜在的分子标和针对MTB的行动机制.
主要方法:
- 17种异酸衍生物的合成.
- 对MTB菌株和耐药临床分离物的抗结核活性体外评估.
- 细胞毒性测定和ADMET预测.
- 对22个MTB蛋白目标进行分子对接.
主要成果:
- 化合物A16和A17在体外表现出最高的抗结核活性,最小抑制度 (MIC) 为10μM.
- 反向分子对接确定了乙烯基-[乙烯基载体蛋白]减少酶作为潜在的生物标.
- A16和A17没有表现出细胞毒性,并且具有有利的ADMET配置文件.
- 这两种化合物都对抗多抗药性临床分离物 (MICs 10-20μM) 显示出有效性.
结论:
- 伊萨衍生物A16和A17具有强效,无毒性,并具有适合于抗结核病治疗的类似药物特性.
- 这些化合物显示出克服多药耐药MTB菌株耐药性机制的潜力.
- A16和A17代表了开发新的抗结核药物的有希望的领先候选人.
相关概念视频
01:25Inhibitors of Bacterial Protein Synthesis
66
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
66
01:28Inhibitors of Bacterial DNA Synthesis
77
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
77